Literature DB >> 12653200

The role of tetrahydrobiopterin in superoxide generation from eNOS: enzymology and physiological implications.

Jeannette Vásquez-Vivar1, B Kalyanaraman, Pavel Martásek.   

Abstract

Tetrahydrobiopterin (BH4) is a ubiquitous pteridine metabolite that serves as a NOS cofactor. Recently, we showed that BH4 efficiently inhibits superoxide generation from the heme group at the oxygenase domain of eNOS. This role indicates that BH4 acts as a redox switch in the catalytic mechanism of the enzyme, which may have important consequences in the physiology of the endothelium. Here the mechanism by which BH4 inhibits superoxide release from eNOS and the "uncoupling" effects of oxidized BH4 metabolites are presented. The implications of the disparate actions of fully reduced and oxidized BH4 metabolites in the control of eNOS biochemistry are discussed in the light of clinical data indicating that BH4 levels are important in the regulation of superoxide levels and of endothelial reactivity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12653200     DOI: 10.1080/1071576021000040655

Source DB:  PubMed          Journal:  Free Radic Res        ISSN: 1029-2470


  54 in total

1.  Tetrahydrobiopterin deficiency and nitric oxide synthase uncoupling contribute to atherosclerosis induced by disturbed flow.

Authors:  Li Li; Wei Chen; Amir Rezvan; Hanjoong Jo; David G Harrison
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-04-21       Impact factor: 8.311

Review 2.  Targeting NADPH oxidases in vascular pharmacology.

Authors:  Agata Schramm; Paweł Matusik; Grzegorz Osmenda; Tomasz J Guzik
Journal:  Vascul Pharmacol       Date:  2012-03-03       Impact factor: 5.773

3.  The role of tetrahydrobiopterin and dihydrobiopterin in ischemia/reperfusion injury when given at reperfusion.

Authors:  Qian Chen; Elizabeth Eun Jung Kim; Katrina Elio; Christopher Zambrano; Samuel Krass; Jane Chun-Wen Teng; Helen Kay; Kerry-Anne Perkins; Sailesh Pershad; Sloane McGraw; Jeffrey Emrich; Jovan S Adams; Lindon H Young
Journal:  Adv Pharmacol Sci       Date:  2010-06-09

Review 4.  Utilization of Vitamin E Analogs to Protect Normal Tissues While Enhancing Antitumor Effects.

Authors:  Nukhet Aykin-Burns; Rupak Pathak; Marjan Boerma; Thomas Kim; Martin Hauer-Jensen
Journal:  Semin Radiat Oncol       Date:  2019-01       Impact factor: 5.934

5.  Hydrogen sulfide treatment reduces blood pressure and oxidative stress in angiotensin II-induced hypertensive mice.

Authors:  Mohammad R Al-Magableh; Barbara K Kemp-Harper; Joanne L Hart
Journal:  Hypertens Res       Date:  2014-08-07       Impact factor: 3.872

6.  Lipopolysaccharide induces inducible nitric oxide synthase-dependent podocyte dysfunction via a hypoxia-inducible factor 1α and cell division control protein 42 and Ras-related C3 botulinum toxin substrate 1 pathway.

Authors:  Ahmad K Mashmoushi; Jim C Oates
Journal:  Free Radic Biol Med       Date:  2015-03-09       Impact factor: 7.376

Review 7.  Thick Ascending Limb Sodium Transport in the Pathogenesis of Hypertension.

Authors:  Agustin Gonzalez-Vicente; Fara Saez; Casandra M Monzon; Jessica Asirwatham; Jeffrey L Garvin
Journal:  Physiol Rev       Date:  2019-01-01       Impact factor: 37.312

8.  Reduced vascular tetrahydrobiopterin (BH4) and endothelial function with ageing: is it time for a chronic BH4 supplementation trial in middle-aged and older adults?

Authors:  Gary L Pierce; Thomas J Larocca
Journal:  J Physiol       Date:  2008-04-03       Impact factor: 5.182

9.  GTP cyclohydrolase I expression is regulated by nitric oxide: role of cyclic AMP.

Authors:  Sanjiv Kumar; Xutong Sun; Shruti Sharma; Saurabh Aggarwal; Kandasamy Ravi; Jeffery R Fineman; Stephen M Black
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-05-15       Impact factor: 5.464

10.  Peroxynitrite modifies the structure and function of the extracellular matrix proteoglycan perlecan by reaction with both the protein core and the heparan sulfate chains.

Authors:  Eleanor C Kennett; Martin D Rees; Ernst Malle; Astrid Hammer; John M Whitelock; Michael J Davies
Journal:  Free Radic Biol Med       Date:  2010-04-21       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.